Table 1 Baseline characteristics of patients with ITP according to the development of SLE

Age, years

52.0 (34.0–61.0)

53.0 (36.0–62.0)

31.5 (24.0–49.8)

0.008

F/U duration, months

74.5 (38–118.5)

79.5 (41.3–119.5)

30 (15.5–105)

0.026

Female sex

90 (69.2)

81 (67.5)

9 (90.0)

0.14

BMI, kg/m²

23.8 ± 3.6

23.9 ± 3.7

22.4 ± 2.6

0.20

HTN

31 (23.8)

30 (25.0)

1 (10.0)

0.45

DM

14 (10.8)

13 (10.8)

1 (10.0)

1.00

Clinical manifestations

 Skin bleeding

71 (54.6)

62 (51.7)

9 (90.0)

0.022

 Mucosa bleeding

22 (16.9)

20 (16.7)

2 (20.0)

0.68

 Organ bleeding

17 (13.1)

11 (9.2)

6 (60.0)

 < 0.001

BM cellularity, %

40 (30–50)

40 (30–45)

48 (30–51)

0.21

BM megakaryocyte, /HPF

2.8 (1.7–4.0)

2.8 (1.7–4.0)

4.1 (1.3–5.3)

0.30

Laboratory findings

 WBC, /μL

5800 (4675–7900)

5800 (4725–7875)

6300 (3750–8700)

0.83

 Lymphocyte count, /μL

1664 (1353–2282)

1713 (1385–2308)

1253 (536–1803)

0.011

 Hemoglobin, g/dL

12.9 (11.2–14.2)

13 (11.5–14.3)

10.9 (10.0–11.4)

0.001

 Platelet count, × 10⁹/L

13 (7.0–25.3)

15 (7.3–26.8)

10 (4.5–13)

0.039

 Pancytopenia

8 (6.2)

6 (5.0)

2 (20.0)

0.12

 Leukopenia^a

19 (14.6)

16 (13.3)

3 (30.0)

0.16

 Neutropenia^b

7 (5.4)

6 (5.0)

1 (10.0)

0.20

 Lymphocytopenia^c

46 (35.4)

39 (32.5)

7 (70.0)

0.033

 Anemia^d

42 (32.3)

34 (28.3)

8 (80.0)

0.002

 Severe thrombocytopenia^e

84 (64.6)

74 (61.7)

10 (100)

0.014

 AST, IU/L

22 (17–27)

22 (17–28)

24 (19–31)

0.54

 ALT, IU/L

19 (13–28)

19 (13–28)

19 (13–23)

0.65

 Creatinine, mg/dL

0.7 (0.6–0.9)

0.7 (0.6–0.9)

0.7 (0.7–0.9)

0.85

 eGFR, mL/min/1.73 m²

92 (78–110)

92 (78–110)

95 (72–109)

0.79

 ANA positivity (≥ 1:160)

16 (12.3)

10 (8.3)

6 (60.0)

 < 0.001